Mylan NV has agreed to pay a $30 million fine to settle SEC charges that it hid the impact of a federal probe into the drugmaker’s overbilling the government for its EpiPen allergy treatment. The SEC on Friday said Mylan kept investors in the dark when it failed to disclose or set aside money for the two-year probe by the DOJ.